Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy.
Polycystic ovary syndrome (PCOS) is a variable disorder characterized by a broad spectrum of anomalies, including hyperandrogenemia, insulin resistance, dyslipidemia, body adiposity, low-grade inflammation and increased cardiovascular disease risks. Recently, a new polytherapy consisting of low-dose...
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2011
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/a609a2e2f41b4e308298f6adaac9d0a5 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:a609a2e2f41b4e308298f6adaac9d0a5 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:a609a2e2f41b4e308298f6adaac9d0a52021-11-18T07:31:55ZMetabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy.1932-620310.1371/journal.pone.0029052https://doaj.org/article/a609a2e2f41b4e308298f6adaac9d0a52011-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22194988/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203Polycystic ovary syndrome (PCOS) is a variable disorder characterized by a broad spectrum of anomalies, including hyperandrogenemia, insulin resistance, dyslipidemia, body adiposity, low-grade inflammation and increased cardiovascular disease risks. Recently, a new polytherapy consisting of low-dose flutamide, metformin and pioglitazone in combination with an estro-progestagen resulted in the regulation of endocrine clinical markers in young and non-obese PCOS women. However, the metabolic processes involved in this phenotypic amelioration remain unidentified. In this work, we used NMR and MS-based untargeted metabolomics to study serum samples of young non-obese PCOS women prior to and at the end of a 30 months polytherapy receiving low-dose flutamide, metformin and pioglitazone in combination with an estro-progestagen. Our results reveal that the treatment decreased the levels of oxidized LDL particles in serum, as well as downstream metabolic oxidation products of LDL particles such as 9- and 13-HODE, azelaic acid and glutaric acid. In contrast, the radiuses of small dense LDL and large HDL particles were substantially increased after the treatment. Clinical and endocrine-metabolic markers were also monitored, showing that the level of HDL cholesterol was increased after the treatment, whereas the level of androgens and the carotid intima-media thickness were reduced. Significantly, the abundance of azelaic acid and the carotid intima-media thickness resulted in a high degree of correlation. Altogether, our results reveal that this new polytherapy markedly reverts the oxidant status of untreated PCOS women, and potentially improves the pro-atherosclerosis condition in these patients.Maria VinaixaMiguel Angel RodriguezSara SaminoMarta DíazAntoni BeltranRoger MallolCinta BladéLourdes IbañezLourdes IbañezXavier CorreigOscar YanesPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 6, Iss 12, p e29052 (2011) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Maria Vinaixa Miguel Angel Rodriguez Sara Samino Marta Díaz Antoni Beltran Roger Mallol Cinta Bladé Lourdes Ibañez Lourdes Ibañez Xavier Correig Oscar Yanes Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy. |
| description |
Polycystic ovary syndrome (PCOS) is a variable disorder characterized by a broad spectrum of anomalies, including hyperandrogenemia, insulin resistance, dyslipidemia, body adiposity, low-grade inflammation and increased cardiovascular disease risks. Recently, a new polytherapy consisting of low-dose flutamide, metformin and pioglitazone in combination with an estro-progestagen resulted in the regulation of endocrine clinical markers in young and non-obese PCOS women. However, the metabolic processes involved in this phenotypic amelioration remain unidentified. In this work, we used NMR and MS-based untargeted metabolomics to study serum samples of young non-obese PCOS women prior to and at the end of a 30 months polytherapy receiving low-dose flutamide, metformin and pioglitazone in combination with an estro-progestagen. Our results reveal that the treatment decreased the levels of oxidized LDL particles in serum, as well as downstream metabolic oxidation products of LDL particles such as 9- and 13-HODE, azelaic acid and glutaric acid. In contrast, the radiuses of small dense LDL and large HDL particles were substantially increased after the treatment. Clinical and endocrine-metabolic markers were also monitored, showing that the level of HDL cholesterol was increased after the treatment, whereas the level of androgens and the carotid intima-media thickness were reduced. Significantly, the abundance of azelaic acid and the carotid intima-media thickness resulted in a high degree of correlation. Altogether, our results reveal that this new polytherapy markedly reverts the oxidant status of untreated PCOS women, and potentially improves the pro-atherosclerosis condition in these patients. |
| format |
article |
| author |
Maria Vinaixa Miguel Angel Rodriguez Sara Samino Marta Díaz Antoni Beltran Roger Mallol Cinta Bladé Lourdes Ibañez Lourdes Ibañez Xavier Correig Oscar Yanes |
| author_facet |
Maria Vinaixa Miguel Angel Rodriguez Sara Samino Marta Díaz Antoni Beltran Roger Mallol Cinta Bladé Lourdes Ibañez Lourdes Ibañez Xavier Correig Oscar Yanes |
| author_sort |
Maria Vinaixa |
| title |
Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy. |
| title_short |
Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy. |
| title_full |
Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy. |
| title_fullStr |
Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy. |
| title_full_unstemmed |
Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy. |
| title_sort |
metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2011 |
| url |
https://doaj.org/article/a609a2e2f41b4e308298f6adaac9d0a5 |
| work_keys_str_mv |
AT mariavinaixa metabolomicsrevealsreductionofmetabolicoxidationinwomenwithpolycysticovarysyndromeafterpioglitazoneflutamidemetforminpolytherapy AT miguelangelrodriguez metabolomicsrevealsreductionofmetabolicoxidationinwomenwithpolycysticovarysyndromeafterpioglitazoneflutamidemetforminpolytherapy AT sarasamino metabolomicsrevealsreductionofmetabolicoxidationinwomenwithpolycysticovarysyndromeafterpioglitazoneflutamidemetforminpolytherapy AT martadiaz metabolomicsrevealsreductionofmetabolicoxidationinwomenwithpolycysticovarysyndromeafterpioglitazoneflutamidemetforminpolytherapy AT antonibeltran metabolomicsrevealsreductionofmetabolicoxidationinwomenwithpolycysticovarysyndromeafterpioglitazoneflutamidemetforminpolytherapy AT rogermallol metabolomicsrevealsreductionofmetabolicoxidationinwomenwithpolycysticovarysyndromeafterpioglitazoneflutamidemetforminpolytherapy AT cintablade metabolomicsrevealsreductionofmetabolicoxidationinwomenwithpolycysticovarysyndromeafterpioglitazoneflutamidemetforminpolytherapy AT lourdesibanez metabolomicsrevealsreductionofmetabolicoxidationinwomenwithpolycysticovarysyndromeafterpioglitazoneflutamidemetforminpolytherapy AT lourdesibanez metabolomicsrevealsreductionofmetabolicoxidationinwomenwithpolycysticovarysyndromeafterpioglitazoneflutamidemetforminpolytherapy AT xaviercorreig metabolomicsrevealsreductionofmetabolicoxidationinwomenwithpolycysticovarysyndromeafterpioglitazoneflutamidemetforminpolytherapy AT oscaryanes metabolomicsrevealsreductionofmetabolicoxidationinwomenwithpolycysticovarysyndromeafterpioglitazoneflutamidemetforminpolytherapy |
| _version_ |
1718423305834201088 |